Literature DB >> 6246209

Successuful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide.

K Ricker, A Haass, R Rüdel, R Böhlen, H G Mertens.   

Abstract

Recent studies have shown that the sodium conductance of the sarcolemma is disturbed in paramyotonia. Tocainide is a new antiarrhythmic agent which seems to reduce effectively sodium conductance. Eight patients with paramyotonia were treated with tocainide, whereby the paramyotonic stiffness and weakness brought about by cooling could be prevented.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6246209      PMCID： PMC490520          DOI： 10.1136/jnnp.43.3.268

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  10 in total

1.  MUSCLE MEMBRANE POTENTIALS IN EPISODIC ADYNAMIA.

Authors:  O D CREUTZFELDT; B C ABBOTT; W M FOWLER; C M PEARSON
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1963-06

2.  Paresis and hyperexcitability in adynamia episodica hereditaria.

Authors:  F BUCHTHAL; L ENGBAEK; I GAMSTORP
Journal:  Neurology       Date:  1958-05       Impact factor: 9.910

3.  Sodium currents in mammalian muscle.

Authors:  R H Adrian; M W Marshall
Journal:  J Physiol       Date:  1977-06       Impact factor: 5.182

4.  Influence of temperature on isometric contraction and passive muscular tension in paramyotonia congenita (Eulenburg).

Authors:  A Haass; K Ricker; G Hertel; R Heene
Journal:  J Neurol       Date:  1979-09       Impact factor: 4.849

5.  Effects of tocainide on left ventricular performance at rest and during acute alterations in heart rate and systemic arterial pressure. An echocardiographic study.

Authors:  W F Ryan; J S Karliner
Journal:  Br Heart J       Date:  1979-02

Review 6.  The subcellular basis for the mechanism of inotropic action of cardiac glycosides.

Authors:  K S Lee; W Klaus
Journal:  Pharmacol Rev       Date:  1971-09       Impact factor: 25.468

7.  Electrocardiographic and hemodynamic effects of tocainide (W-36095) in man.

Authors:  K Swedberg; J Pehrson; L Rydén
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

8.  Effects of tocainide on normal and myotonic mammalian skeletal muscle.

Authors:  R Dengler; R Rüdel
Journal:  Arzneimittelforschung       Date:  1979

9.  Spin label study of erythrocyte membrane fluidity in myotonic and Duchenne muscular dystrophy and congenital myotonia.

Authors:  D A Butterfield; D B Chesnut; S H Appel; A D Roses
Journal:  Nature       Date:  1976-09-09       Impact factor: 49.962

10.  Myotonia not aggravated by cooling. Force and relaxation of the adductor pollicis in normal subjects and in myotonia as compared to paramyotonia.

Authors:  K Ricker; G Hertel; K Langscheid; G Stodieck
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849
  10 in total
  10 in total

1.  Neuromyotonia in hereditary motor neuropathy.

Authors:  A F Hahn; A W Parkes; C F Bolton; S A Stewart
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

2.  Tocainide and myotonic dystrophy.

Authors:  R Harries-Jones
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

3.  The different use dependences of tocainide and benzocaine are correlated with different effects on sodium channel inactivation.

Authors:  A DeLuca; T Pröbstle; H Brinkmeier; R Rüdel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

4.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

5.  Improved therapy of myotonia with the lidocaine derivative tocainide.

Authors:  R Rüdel; R Dengler; K Ricker; A Haass; W Emser
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

Review 6.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

Review 7.  The nondystrophic myotonias.

Authors:  Chad R Heatwole; Richard T Moxley
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

8.  A quantitative measure of handgrip myotonia in non-dystrophic myotonia.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Jaya R Trivedi; Dipa Raja Rayan; Laura Herbelin; Merideth Donlan; Rhonda McLin; Katy J Eichinger; Karen Findlater; Liz Dewar; Shree Pandya; William B Martens; Shannon L Venance; Emma Matthews; Anthony A Amato; Michael G Hanna; Robert C Griggs; Richard J Barohn
Journal:  Muscle Nerve       Date:  2012-10       Impact factor: 3.217

9.  Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert.

Authors:  U Mielke; A Haass; S Sen; W Schmidt
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

Review 10.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.